Home >> Research Area >>Metabolism>>Lipid Metabolism>> (±)-Decanoylcarnitine chloride

(±)-Decanoylcarnitine chloride

cholinergic agonist CAS# 14919-36-9

(±)-Decanoylcarnitine chloride

2D Structure

Catalog No. BCC6659----Order now to get a substantial discount!

Product Name & Size Price Stock
(±)-Decanoylcarnitine chloride: 5mg $12 In Stock
(±)-Decanoylcarnitine chloride: 10mg Please Inquire In Stock
(±)-Decanoylcarnitine chloride: 20mg Please Inquire Please Inquire
(±)-Decanoylcarnitine chloride: 50mg Please Inquire Please Inquire
(±)-Decanoylcarnitine chloride: 100mg Please Inquire Please Inquire
(±)-Decanoylcarnitine chloride: 200mg Please Inquire Please Inquire
(±)-Decanoylcarnitine chloride: 500mg Please Inquire Please Inquire
(±)-Decanoylcarnitine chloride: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of (±)-Decanoylcarnitine chloride

3D structure

Package In Stock

(±)-Decanoylcarnitine chloride

Number of papers citing our products

Chemical Properties of (±)-Decanoylcarnitine chloride

Cas No. 14919-36-9 SDF Download SDF
PubChem ID 24802062 Appearance Powder
Formula C17H34ClNO4 M.Wt 351.91
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 100 mM in water
Chemical Name (3-carboxy-2-decanoyloxypropyl)-trimethylazanium;chloride
SMILES CCCCCCCCCC(=O)OC(CC(=O)O)C[N+](C)(C)C.[Cl-]
Standard InChIKey KETNUEKCBCWXCU-UHFFFAOYSA-N
Standard InChI InChI=1S/C17H33NO4.ClH/c1-5-6-7-8-9-10-11-12-17(21)22-15(13-16(19)20)14-18(2,3)4;/h15H,5-14H2,1-4H3;1H
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of (±)-Decanoylcarnitine chloride

DescriptionHomolog of acetylcarnitine chloride.

(±)-Decanoylcarnitine chloride Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

(±)-Decanoylcarnitine chloride Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of (±)-Decanoylcarnitine chloride

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.8416 mL 14.2082 mL 28.4164 mL 56.8327 mL 71.0409 mL
5 mM 0.5683 mL 2.8416 mL 5.6833 mL 11.3665 mL 14.2082 mL
10 mM 0.2842 mL 1.4208 mL 2.8416 mL 5.6833 mL 7.1041 mL
50 mM 0.0568 mL 0.2842 mL 0.5683 mL 1.1367 mL 1.4208 mL
100 mM 0.0284 mL 0.1421 mL 0.2842 mL 0.5683 mL 0.7104 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on (±)-Decanoylcarnitine chloride

(±)-Decanoylcarnitine chloride is an agonist for cholinergic and a homolog of acetylcarnitine chloride (Cat No. B6273).

Acetylcholine receptor (AChR) is an integral membrane protein receptor for acetylcholine. There are two kinds of AChRs: nicotinic acetylcholine receptors and muscarinic acetylcholine receptors.

(±)-Decanoylcarnitine chloride is a cholinergic agonist and an intermediate in lipid metabolism [1]. In retinal ganglion cells, acetylcarnitine and acetylcholine inhibited GABAergic responses to exogenous GABA and GABAergic inhibitory postsynaptic currents [2].

In dogs with coronary ligation, (-)-carnitine chloride (LCC) (300 mg/kg) and acetyl (-)-carnitine chloride (ALCC) (300 mg/kg) inhibited the ventricular arrhythmia. Also, LCC and ALCC improved oxidative phosphorylation rate and the mitochondrial function [1]. In the mouse hot plate test, acetyl-l-carnitine (ALCAR) (100 mg/kg) exhibited analgesia. While, U-73122 and neomycin (the phospholipase C (PLC) inhibitors) blocked the increase of the pain threshold induced by ALCAR. LiCl that impairing phosphatidylinositol synthesis antagonized the antinociception in a dose-dependent way. PMA and PDBu (PKC activators) blocked the increase of the pain threshold in a dose-dependent way. These results suggested that ALCAR analgesia required the participation of the PLC-IP3 pathway [3].

References:
[1].  Imai S, Matsui K, Nakazawa M, et al. Anti-arrhythmic effects of (-)-carnitine chloride and its acetyl analogue on canine late ventricular arrhythmia induced by ligation of the coronary artery as related to improvement of mitochondrial function. Br J Pharmacol, 1984, 82(2): 533-542.
[2].  B?hring R, Standhardt H, Martelli EA, et al. GABA-activated chloride currents of postnatal mouse retinal ganglion cells are blocked by acetylcholine and acetylcarnitine: how specific are ion channels in immature neurons? Eur J Neurosci, 1994, 6(7): 1089-1099.
[3].  Galeotti N, Bartolini A, Calvani M, et al. Acetyl-L-carnitine requires phospholipase C-IP3 pathway activation to induce antinociception. Neuropharmacology, 2004, 47(2): 286-294.

Featured Products
New Products
 

References on (±)-Decanoylcarnitine chloride

Determination of acylcarnitines in urine of patients with inborn errors of metabolism using high-performance liquid chromatography after derivatization with 4'-bromophenacylbromide.[Pubmed:8222273]

Clin Chim Acta. 1993 Jul 16;216(1-2):53-61.

A high-performance liquid chromatographic method is presented for the determination of urinary acylcarnitines. After solid phase extraction on silica columns the acylcarnitines are converted to 4'-bromophenacyl esters with 4'-bromophenacylbromide in the presence of N,N-diisopropylethylamine. Complete derivatization was achieved at 37 degrees C within 30 min. The 4'-bromophenacyl esters were separated by high-performance liquid chromatography on a Hypersil BDS C8 reversed-phase column with a binary gradient containing varying proportions of acetonitrile, water and 0.1 M triethylamine phosphate buffer. Essentially baseline separation was obtained with a standard mixture containing 4'-bromophenacyl esters of carnitine and synthetic acylcarnitines of increasing chain length ranging from acetyl- to palmitoylcarnitine. The method was used to obtain urinary acylcarnitine profiles from patients with propionic, methylmalonic and isovaleric acidemia and with medium-chain and multiple acyl-CoA dehydrogenase deficiency. Quantification of the acylcarnitines was achieved using undecanoylcarnitine as internal standard.

Molecular basis of mitochondrial fatty acid oxidation defects.[Pubmed:1431593]

J Lipid Res. 1992 Aug;33(8):1099-110.

A dozen separate inherited disorders of mitochondrial fatty acid beta-oxidation have been described in humans. This represents about half of the potential sites for genetic error that can affect this important pathway of energy metabolism. As the characterization of these disorders at the clinical and biochemical levels has progressed rapidly, so has the delineation of the molecular defects that underlie them. The most commonly recognized disorder of beta-oxidation is medium-chain acyl-CoA dehydrogenase deficiency; a striking feature of this disorder is that there is a single point mutation that accounts for 90% of the variant alleles among patients with medium-chain acyl-CoA dehydrogenase deficiency. Molecular defects of other enzymes in the pathway have been identified, and it seems likely that a complete description of these defects at the molecular level is a realistic goal. In basic biological terms, such studies will lead to a better understanding of the genetic control exerted on this pathway. In clinical terms, they will lead to improved understanding of the molecular pathophysiology of these diseases and may well provide the necessary techniques to proceed with the screening of these disorders.

Urinary excretion of l-carnitine and acylcarnitines by patients with disorders of organic acid metabolism: evidence for secondary insufficiency of l-carnitine.[Pubmed:6441143]

Pediatr Res. 1984 Dec;18(12):1325-8.

Concentrations of l-carnitine and acylcarnitines have been determined in urine from patients with disorders of organic acid metabolism associated with an intramitochondrial accumulation of acyl-CoA intermediates. These included propionic acidemia, methylmalonic aciduria, isovaleric acidemia, multicarboxylase deficiency, 3-hydroxy-3-methylglutaric aciduria, methylacetoacetyl-CoA thiolase deficiency, and various dicarboxylic acidurias including glutaric aciduria, medium-chain acyl-CoA dehydrogenase deficiency, and multiple acyl-CoA dehydrogenase deficiency. In all cases, concentrations of acylcarnitines were greatly increased above normal with free carnitine concentrations ranging from undetectable to supranormal values. The ratios of acylcarnitine/carnitine were elevated above the normal value of 2.0 +/- 1.1. l-Carnitine was given to three of these patients; in each case, concentrations of plasma and urine carnitines increased accompanied by a marked increase in concentrations of short-chain acylcarnitines. These acylcarnitines have been examined using fast atom bombardment mass spectrometry in some of these diseases and have been shown to be propionylcarnitine in methylmalonic aciduria and propionic acidemia, isovalerylcarnitine in isovaleric acidemia, and hexanoylcarnitine and octanoylcarnitine in medium-chain acyl-CoA dehydrogenase deficiency. The excretion of these acylcarnitines is compatible with the known accumulation of the corresponding acyl-CoA esters in these diseases. In this group of disorders, the increased acylcarnitine/carnitine ratio in urine and plasma indicates an imbalance of mitochondrial mass action homeostasis and, hence, of acyl-CoA/CoA ratios. Despite naturally occurring attempts to increase endogeneous l-carnitine biosynthesis, there is insufficient carnitine available to restore the mass action ratio as demonstrated by the further increase in acylcarnitine excretion when patients were given oral l-carnitine.(ABSTRACT TRUNCATED AT 250 WORDS)

Keywords:

(±)-Decanoylcarnitine chloride,14919-36-9,Natural Products,Lipid Metabolism, buy (±)-Decanoylcarnitine chloride , (±)-Decanoylcarnitine chloride supplier , purchase (±)-Decanoylcarnitine chloride , (±)-Decanoylcarnitine chloride cost , (±)-Decanoylcarnitine chloride manufacturer , order (±)-Decanoylcarnitine chloride , high purity (±)-Decanoylcarnitine chloride

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: